NCT07363252 Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
| NCT ID | NCT07363252 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Gruppo Oncologico Italiano di Ricerca Clinica |
| Condition | EGFR-mutated NSCLC |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-04-14 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2026-04-14 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Retrospective-prospective observational multicentric study including radically resected EGFR-mutated NSCLC patients relapsed during or after adjuvant osimertinib, received according to clinical practice
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of radically resected IB-IIIA NSCLC with EGFR activating mutation * Treatment with adjuvant osimertinib (starting from September 2022, date of approval) according to clinical practice * Recurrence of disease during or after adjuvant therapy with osimertinib received according to clinical practice * Availability of tissue and/or liquid biopsy sample collected at the time of recurrence * Signed informed consent. * Exclusion Criteria: * Unavailability of tissue and/or liquid biopsy sample collected at the time of recurrence * Concomitant synchronous malignancies aside from NSCLC or any concurrent and/or active malignancy that has required treatment within 2 years * Involvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07363252 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying EGFR-mutated NSCLC. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07363252 currently recruiting?
Yes, NCT07363252 is actively recruiting participants. Contact the research team at aleonetti@ao.pr.it for enrollment information.
Where is the NCT07363252 trial being conducted?
This trial is being conducted at Bari, Italy, Bergamo, Italy, Bologna, Italy, Misterbianco, Italy and 11 additional locations.
Who is sponsoring the NCT07363252 clinical trial?
NCT07363252 is sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. The trial plans to enroll 100 participants.